VESICARE

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Cyprus, Estonia, Finland, France, Germany, Hong Kong SAR China, Israel, Japan, Lithuania, Malta, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug VESICARE contains one active pharmaceutical ingredient (API):

1	Solifenacin UNII KKA5DLD701 - SOLIFENACIN SUCCINATE
	Solifenacin is a competitive, specific cholinergic-receptor antagonist. In vitro and in vivo pharmacological studies indicate that solifenacin is a competitive inhibitor of the muscarinic M3 subtype receptor.
	Read more about Solifenacin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VESICARE Oral suspension	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G04BD08	Solifenacin	G Genito urinary system and sex hormones → G04 Urologicals → G04B Other urologicals, incl. antispasmodics → G04BD Urinary antispasmodics
Discover more medicines within G04BD08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	540300202114215, 540300204117211, 540300208112214, 540300210117211
CA	Health Products and Food Branch	02277263, 02277271
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	16956775, 16956781
EE	Ravimiamet	1162415, 1162426, 1162437, 1162448, 1162459, 1162460, 1162471, 1162482, 1162493, 1162505, 1162516, 1162527, 1162538, 1162549, 1162550, 1162561, 1178333, 1178344, 1442720, 1442731, 1668168
ES	Centro de información online de medicamentos de la AEMPS	34009936551671, 34081, 365516, 66257, 66258, 66671854, 80116, RVG29152
FI	Lääkealan turvallisuus- ja kehittämiskeskus	018594, 018677, 018685, 018694, 087572
FR	Base de données publique des médicaments	60608174, 66671854, 67862887
GB	Medicines & Healthcare Products Regulatory Agency	198761, 198763, 358489, 368096, 368098, 369029, 373743, 373805, 377086, 377088, 379986, 379987, 80453, 80456
HK	Department of Health Drug Office	54340, 54341
HR	Agencija za lijekove i medicinske proizvode	HR-H-010904082, HR-H-664354012, HR-H-748673544
IL	מִשְׂרַד הַבְּרִיאוּת	6000, 6001
JP	医薬品医療機器総合機構	2590011F1028, 2590011F2024, 2590011F3020, 2590011F4027
LT	Valstybinė vaistų kontrolės tarnyba	1017425, 1017426, 1017427, 1017428, 1017429, 1017430, 1017431, 1017432, 1017433, 1017434, 1017435, 1017436, 1017437, 1017438, 1017439, 1017440, 1022602, 1022603, 1053691, 1053692, 1074815
MT	Medicines Authority	MA1387/00301, MA1387/00302, MA1387/00303, PI908/18801A
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	628M2005
NL	Z-Index G-Standaard, PRK	167215, 75337, 75345
NZ	Medicines and Medical Devices Safety Authority	11982, 11983
PL	Rejestru Produktów Leczniczych	100134878, 100134890, 100330332
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W43104001, W43105001, W62488001
SG	Health Sciences Authority	13702P, 13703P
TN	Direction de la Pharmacie et du Médicament	4453021, 4453022
TR	İlaç ve Tıbbi Cihaz Kurumu	8699043890369, 8699043890376, 8699043890383, 8699043890390
US	FDA, National Drug Code	51248-150, 51248-151, 51248-250, 55154-3877, 55154-3878, 70518-1866
ZA	Health Products Regulatory Authority	A39/5.4/0490, A39/5.4/0491